Abstract
2606 Background: Melanoma patients with lymph node metastasis at diagnosis have a less than 60% survival rate at 5 years. Interferon-a (IFNa) is used as adjuvant treatment for such patients, even though recent studies showed no increase in survival. Vaccination with tumor-specific MAGE peptides may induce tumor regression in 10–20% of metastatic melanoma patients, mostly those with only subcutaneous or lymph node metastases. However, cytolytic T lymphocyte (CTL) responses to the vaccine antigens have been observed only in half of the patients with tumor regression. We examined whether IFNa could serve as an adjuvant to induce CTL responses against tumor-specific peptides in mice and in melanoma patients without evidence of disease. Methods and Results: No detectable CTL responses can be observed in DBA/2 mice vaccinated with 50 ug of peptide P1A, which is carried on mastocytoma cells P815, injected subcutaneously without adjuvant. In the presence of immunological adjuvant AS02B (QS21/MPL from GlaxoSmithKl...
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
